Semaglutide: The Drug that May Lead to a 'New Era' in Anti-Obesity Medication
Historically, most weight-loss drugs can only reduce weight by 5-10%, and there are many hidden safety risks. In clinical trials, smeglutide not only reduced the weight of obese patients by an average of 15%, but also showed good safety.
As scientists have a deeper understanding of the molecular mechanism of signal communication between the intestine and the brain, a variety of new generations of weight loss therapies are emerging. Recently, a review of Nature Reviews Drug Discovery, a sub-published by Nature, counted these innovative therapies.
Both Tirzepatide and smeglutide reduced the weight of obese patients by more than 10% in phase 3 clinical trials, breaking the historical limitation that weight loss drugs can only reduce weight by 5% to 10%. The review authors stated that they set a new benchmark for the development of a new generation of weight-loss drugs.
You May Interested In
2026-10-09
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
![Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials]()
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
![Colombia Makes Preliminary Ruling in Anti-Dumping Investigation into Chinese DOP Imports]()
Colombia Makes Preliminary Ruling in Anti-Dumping Investigation into Chinese DOP Imports
-
![India Proposes New GMP Rules for Clinical Trial and API Manufacturing]()
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
![Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue]()
Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue
-
![FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers]()
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
![Business Society September 22, 2026 Caustic Soda Trend Analysis: Bullish Outlook]()
Business Society September 22, 2026 Caustic Soda Trend Analysis: Bullish Outlook
-
![Business Society September 22, 2026 Cyclohexanone Trend Analysis: Volatile and Bearish]()
Business Society September 22, 2026 Cyclohexanone Trend Analysis: Volatile and Bearish
-
![What is Aconitic Acid? (Chemistry & Occurrence)]()
What is Aconitic Acid? (Chemistry & Occurrence)
-
![Polyester Bottle Flakes Show Intraday Volatility and Strength on the 23rd, Closing Higher at Late Trading Hours]()
Polyester Bottle Flakes Show Intraday Volatility and Strength on the 23rd, Closing Higher at Late Trading Hours
-
![Business Society PVC Trend Analysis for September 22, 2026: Range-bound Fluctuations]()
Business Society PVC Trend Analysis for September 22, 2026: Range-bound Fluctuations
